-
Wider Use of SGLT2 Inhibitors for CVD Recommended by NICE Opens in a new window)
NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD). -
Cholesterol-Busting Drug Could Save Thousands of Lives
The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.Comments
-
EMA Lays Out Plans For Routine Use Of Real-World Evidence Opens in a new window)
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.Comments
-
NICE Recommends Novartis’ Cosentyx for Children with Severe Psoriasis Opens in a new window)
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.Comments
-
Pharmaceutical Pricing Policy Expected to Go in Force in October Opens in a new window)
Passed by cabinet in October last year, the policy is aimed at regulating the prices of pharmaceutical products with a view to putting an end to pricing malpractices by different players in the industry.Comments
-
China Ramps Up Healthcare Reform with Pilot Pricing Scheme Opens in a new window)
China will reform the pricing of medical services provided by public hospitals as part of its campaign to make healthcare more affordable.Comments
-
International Reference Pricing: There Are Better Options to Address Patients’ Drug Costs
International Reference Pricing sounds great on paper but would unfortunately harm older adults and individuals with a disability.Comments
-
Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA Opens in a new window)
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy.Comments
-
UK’s NICE Recommends Anti-Cholesterol Leqvio for High-Risk Patients Opens in a new window)
The decision follows the agreement of a “population-level commercial deal” between the NHS and Novartis to make Leqvio “available with a discount to its list price”, said NICE.Comments
-
Novartis Finalizes Deal to Make New Heart Drug Widely Available in England Opens in a new window)
Leqvio costs nearly 2,000 pounds, or about $2,750, per 284-milligram pack, but NICE negotiated a deal for what NHS describes as an "affordable and cost-effective price".Comments
-
With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doses Opens in a new window)
Even if Medicare decides to pay, patients generally would be responsible for 20 percent plus the cost of required testing and imaging.Comments
-
Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel Opens in a new window)
ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.Comments
-
NICE Recommends Novartis’ Rydapt for Advanced SM Treatment Opens in a new window)
Rydapt is the first and only licensed treatment for advanced SM in the UK and has been shown to provide therapeutic benefits to adults with the disease.Comments
-
Insurer Price Transparency Rule Faces Legal Challenges: 4 Takeaways Opens in a new window)
In the past two weeks, the U.S. Chamber of Commerce and the Pharmaceutical Care Management Association have filed lawsuits challenging the price transparency rule for health insurers.Comments
-
Cutting Square Deals: Drug Prices, Regulation, and Patent Protection
Canada’s efforts to reduce pharmaceutical prices should not come at the cost of contributing our fair share to developing new treatment innovations, and should rely more on negotiations with manufacturers than regulation.Comments
Comments